Modulation of plasminogen activator inhibitor type-1 biosynthesis in vitro and in vivo with oligo(nucleoside phosphorothioate)s and related constructs

Pharmacology and Therapeutics

Volumn 76, Issue 1-3, 1997, Pages 161-175

  Buczko, Wlodzimierz ^a   Cierniewski, Czeslaw ^b   Kobylańska, Anna ^c   Koziolkiewicz, Maria ^c   Okruszek, Andrzej ^c   Pawlowska, Zofia ^b   Pluskota, Elzbzieta ^b   Stec, Wojciech J ^c  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

^b MEDICAL UNIVERSITY OF LODZ   (Poland)

^c POLISH ACADEMY OF SCIENCES   (Poland)

Author keywords

Antisense inhibition; Bioconjugates; Oligonucleotides; PAI 1; Phosphorothioates

Indexed keywords

OLIGODEOXYNUCLEOTIDE PHOSPHOROTHIOATE; PLASMINOGEN ACTIVATOR INHIBITOR 1;

DOSE RESPONSE; ENDOTHELIUM CELL; FIBRINOLYSIS; HUMAN; HUMAN CELL; NUCLEOTIDE METABOLISM; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; RECEPTOR DOWN REGULATION; REVIEW; SMOOTH MUSCLE FIBER; VASCULAR ENDOTHELIUM;

ANIMALS; HUMANS; OLIGONUCLEOTIDES, ANTISENSE; PLASMINOGEN ACTIVATOR INHIBITOR 1; RNA, MESSENGER; STRUCTURE-ACTIVITY RELATIONSHIP; THIONUCLEOTIDES;

EID: 0031278020     PISSN: 01637258     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0163-7258(97)00091-0     Document Type: Review

References (92)

1. Agatsuma, T., Yamamoto, I., Furukawa, H. and Nishigaki, T. (1996) Guanine-rich oligonucleotide modified at the 5′ terminal by dimethoxytrityl residue inhibits HIV-1 replication by specific interaction with the envelope glycoprotein. Antiviral Res. 31: 137-148.
2. Agrawal, S. (ed.) (1996a) Antisense Therapeutics. Humana Press, Totowa.
3. Agrawal, S. (1996b) Antisense oligonucleotides: towards clinical trials. Trends Biotechnol. 14: 576-387.
4. Andreasen, P. A., Pyke, C., Riccio, A., Kristensen, P., Nielsen, L. S., Lund, L. R., Blasi, F. and Dano, K. (1987) Plasminogen activator inhibitor type 1 biosynthesis and mRNA level are increased by dexamethasone in human fibrosarcoma cells. Mol. Cell. Biol. 7: 3021-3025.
5. Auwerx, J., Bouillon, R., Collen, D. and Geboers, J. (1988) Tissue-type plasminoyen activator antigen and plasminogen activator inhibitor in diabetes mellitus. Arteriosclerosis 8: 68-72.
6. Biemond, B. J., Levi, M., Coronel, R., Janse, M. J., ten Cate J. W. and Pannekoek, H. (1995) Thrombolysis and reocclusion in experimental jugular vein and coronary artery thrombosis: effects of a plasminogen activator inhibitor type 1 neutralizing monoclonal antibody. Circulation 91: 1175-1181.
7. Boiziau, C. and Toulme, J. J. (1991) Modified oligonucleotides in rabbit reticulocytes: uptake, stability and antisense properties. Biochimie 73: 1403-1408.
8. Bosma, P. J., van den Berg, E. A., Kooistra, T., Siemiemak, D. R. and Slightom, J. L. (1988) Human plasminogen activator inhibitor-1 gene: promoter and structural gene nucleotide sequences. J. Biol. Chem. 263: 9129-9141.
9. Charlton, P. A., Faint, R. W., Bent, F., Bryans, J., Mackie, I., Machin, S. and Bevan, P. (1995) A series of low molecular weight inhibitors ot plasminogen activator inhibitor-1 increase fibrinolysis and protect against thrombus formation in the rat Thromb. Haemost. 73: 1005.
10. Charlton, P. A., Faint, R. W., Bent, F., Bryans, J., Chicarelli-Robinson, I., Mackie, I., Machin, S. and Bevan, P. (1996) Evaluation of a low molecular weight modulator of human plasmmogen activator inhibitor-1 activity. Thromb. Haemost. 75: 808-815.
11. Cierniewski, C. S., Babińska, A., Swiatkowska, M., Wilczyńska, M., Okruszek, A. and Stec, W. J. (1995a) Comparative inhibition of PAI-1 expression in human endothelial cells by modified oligodeoxyribonucleotides. Eur. J. Biochem. 227: 494-499.
12. Cierniewski, C. S., Pluskota, E., Krzesłowska, J., Fijalkrowska, I., Kobylańska, A., Koziołkiewicz, M., Okruszek, A. and Stec, W. J. (1995b) Inhibition by modified oligodeoxyribonucleotides of the expression of the type I plasimnogen activator inhibitor in human endothelial cells. Thromb. Haemost. 73: 1007.
13. Colucci, M., Paramo, J. A. and Collen, D. (1986) Inhibition of one-chain and two-chain forms of human tissue-type plasminogen activalor by the fast-acting inhibitor of plasminogein activator in vitro and in vivo. J. Lab. Clin. Med. 108: 53-59.
14. Declerck, P. J., Alessi, M. C., Varstreken, M., Kruithof, E. K., Juhan-Vague, I. and Collen. D. (1988) Measurement of plasminogen activator inhibitor 1 in biologic fluids with a murine monoclonal antibody-based enzyme-linked immunosorbent assay. Blood 71: 220-225.
15. De Mesmaeker, A., Häner, R., Martin, P. and Moser, H. E. (1995) Antisense oligonucleotides. Acc. Chem. Res. 28: 366-374.
16. Dichek, D. and Quertermous, T. (1989) Thrombin regulation of mRNA levels of tissue plasminogen activator and plasminogen activator inhibitor-1 in cultured human umbilical vein endothelial cells. Blood 74: 222-228.
17. Eckstein, F. (1985) Nucleoside phosphorothioates. Annu. Rev. Biochem. 54: 367-402.
18. Egholm, M., Buchardt, O., Christensen, L., Behrens, C., Freier, S. M., Driver, D. A., Berg, R. H., Kim. S. K., Norden, B. and Nielsen, P. E. (1993) PNA hybridizes to complementary oligonucleotides obeying the Watson-Crick hydrogen-bonding rules. Nature 365: 566-568.
19. Eitzman, D. T., Fay, W. P., Lawrence, D. A., Francis-Chmura, A. M., Shore, J. D., Olson, S. T. and Ginsburg, D. (1995) Peptide-mediated inactivation of recombinant and platelet plasminogen activator inhibitor-1 in vivo. J. Clin. Invest. 95: 2416-2420.
20. Erickson, L. A., Hekman, C. M. and Loskutoff, D. J. (1986) Denaturant-induced stimulation of the beta-migrating plasminogen activator inhibitor in endothelial cells and serum. Blood 68: 1298-1305.
21. Erickson, L. A., Fici, G. J., Lund, J. E., Boyle, T. P., Polites, H. G. and Marotti, K. R. (1990) Development of venous occlusions in mice transgenic for the plasminogen activator inhibitor 1 gene. Nature 346: 74-76.
22. Etingin, O. R., Hajjar, D. P., Hajjar, K. A., Harpel, P. C. and Nachman, R. L. (1991) Lipoprotein(a) regulates plasminogen activator inhibitor-1 expression in endothelial cells: a potential mechanism in thrombogenesis. J. Biol. Chem. 260: 2459-2465.
23. Fisher, T. L., Terhorst, T., Cao, X. and Wagner, R. W. (1993) Intracellular disposition and metabolism of fluourescently-labeled unmodified and modified oligonucleotides microinjected into mammalian cells. Nucl. Acids Res. 21: 3857-3865.
24. Froehler, B. C. (1986) Deoxynucleoside H-phosphonate diester intermediates in the synthesis of internucleotide phosphate analogues. Tetrahedron Lett. 27: 5575-5578.
25. Gao, W., Han, F., Storm, C., Egan, W. and Cheng, Y (1991) Phosphorothioate oligonucleotides are inhibitors of human DNA polymerases and RNase H: implications for antisense technology. Mol. Pharmacol. 41: 223-229.
26. Gelehrter, T. D., Barouski-Miller, P. A., Coleman, P. L. and Cwikel, B. J. (1983) Hormonal regulation of plasminogen activator in rat hepatoma cells. Mol. Cell. Biochem. 53-54: 11-21.
27. Goodchild, J. (1990) Conjugates of oligonucleotides and modified oligonucleotides: a review of their synthesis and properties. Bioconjug. Chem. 1: 165-187.
28. Habus, I., Zhao, Q. and Agrawal, S. (1995) Synthesis, hybridization properties, nuclease stability, and cellular uptake of the oligonucleotide-amino-β-cyclodextrins and adamantane conjugates. Bioconjug. Chem. 6: 327-331.
29. Hacia, J. G., Wold, B. J. and Dervan, P. B. (1994) Phosphorothioate oligonucleotide-directed triple helix formation. Biochemistry 33: 5367-5369.
30. Hamsten, A., Wiman, B., de Faire, U. and Blomback, M (1985) Increased plasma levels of a rapid inhibitor o tissue plasminogen activator in young survivors of myocardial infarction. N. Engl. J. Med. 313: 1557-1563.
31. Hamsten, A., de Faire, U., Walldius, G., Dahlen, G., Szamosi, A., Landou, C., Blomback, M. and Wiman, B. (1987) Plasminogen activator inhibitor in plasma risk factor for recurrent myocardial infarction. Lancet ii: 3-9.
32. Hekman, C. M. and Loskutoff, D. J. (1985) Endotbelial cells produce a latent inhibitor ot plasminogen activators that can be activated by denaturants. J. Biol. Chem. 260: 11581-11587.
33. Herschlag, D. (1991) Implications of ribozyme kinetics for targeting the cleavage of specific RNA molecules in vivo: more isn't always better. Proc. Natl. Acad. Sci. USA 88 6921-6925.
34. Hornstra, G. and Vendelmans-Starrenhurg, A. (1973) Induction of experimental occlusive thrombi in rats. Atherosclerosis 17: 369-382.
35. Jaffe, E. A., Minick, C. R., Adelman, B., Becker, C. G. and Nachman, R. L. (1976) Synthesis of basement membrane colagen by cultured human endothelial cells. J. Exp. Med. 144: 209-225.
36. Jaschke, A., Furste, J. P., Nordhoff, E., Hillenkamp, F., Cech, D. and Erdmann, V. A. (1994) Synthesis and propeties of oligodeoxyribonucleotide-polyethylene glycol conjugate. Nucl. Acids Res. 22: 4810-4817.
37. Jaschke, A., Bald, R., Nordhoff, E., Hillenkamp, F., Cech, D., Erdmann, B. A. and Furste, J. P. (1996) Synthesis and analytical characterization of RNA-polyethylene glycol conjugates. Nucleosides Nucleotides 15: 1519-1529.
38. Keski-Oja, J., Raghow, R., Sawdey, M., Loskutoff, D. J., Postlethwaite, A. E., Kang, A. H. and Moses, H. L. (1988) Regulation of mRNAs tor type-1 plasminogen activator inhibitor, fibronectin, and type I procollagen by transforming growth fctaor-beta: divergent responses in lung fibroblasts and carcinoma cells. J. Biol. Chem. 263: 3111-3115.
39. Kessler, S. W. (1975) Rapid isolation ot antigens from cells with a staphylococcal protein A-antibody absorbent: parameters of the interaction of antibody-antigen complexes with protein A. J. Immunol. 115: 1617-1624.
40. Knorre, D. G. and Zarytova, V. F. (1991) Novel antisense derivatives: antisense DNA interkalators, cleavers, and alkylators. In: Prospects for Antisense Nucleic Acid Therapy of Cancer and AIDS, pp. 195-218, Wickstrom, E. (ed.) Wiley-Liss, New York.
41. Knudsen, B. S., Harpel, P. C. and Nachman, R. L. (1987) Plasminogen activator inhibitor is associated with the extracellular matrix of cultured bovine smooth muscle cell. J. Clin. Invest. 80: 1082-1089.
42. Kooistra, T., Sprengers, E. D. and van Hinsbergh, V. W. (1986) Rapid inactivation of the plasminogen-activator inhibitor upon secretion from cultured human endothelial cells. Biochem. J. 239: 497-503.
43. Koziołkiewiez, M. and Stec, W. J. (1992) The application of phosphate-backbone modified oligonucleotides in the studies on Eco RI endonuclease mechanism of action. Biochemistry 31: 9460-9466.
44. Koziołkiewicz, M., Krakowiak, A., Kwinkowski, M., Boczkowska, M. and Stec, W. J. (1995) Stereodifferentiation: the effect of P chirality of oligo(nucleoside phosphorothioates) on the activity of bacterial RNase H. Nucl. Acids Res. 23: 5000-5005.
45. Koziołkiewicz, M., Uznański, B., Stec, W. J. and Zon, G. (1986) P-chiral analogues ot oligodeoxyribonucleotides: synthesis, stereochemistry and enzyme studies. Chem. Scr. 26: 251-260.
46. Koziołkiewicz, M., Wójcik, M., Kobylańska, A., Karwowski, B., Rȩbowska, B., Guga, P. and Stec, W. J. (1997) Stability of stereoregular oligo(nuelcoside phosphorothioate)s in human plasma: diastereoselectivity of plasma 3′-exonuclease. Antisense Nucl. Acids Drug Dev. 7 43-48.
47. Krishnamurti, C. and Alving, B. M. (1992) Plasminogen activator inhibitor type 1: biochemistry and evidence for modulation of fibrinolysis in vivo. Semin. Thromb. Hemost. 18: 67-80.
48. Kruirhof, E. K., Nicolosa, G. and Bachmann, F. (1987) Plasminogen activator inhibitor 1: development of radioimmunoassay and observations on its plasma concentration during venous occlusion and after platelet aggregation. Blood 70: 1645-1653.
49. 2 and H-Phe-Ser(pGC)-Ala-OH via a phosphotriester approach. Nucl. Acids Res. 17: 2897-2905.
50. P oligonucleotide phosphorothioates. Biotechnol. Lett. 19: 475-478.
51. Leonetti, J. P., Rayner, B., Lemaitre, M., Gagnor, C., Milhaud, P. G., Imhach, J.-L. and Lebleu, B. (1988) Antiviral activity of conjugales between poly(L-lysine) and synthetic oligodeoxyribonucleotides. Gene 72: 323-332.
52. Leśnikowski, Z. J. (1993) Stereocontrolled synthesis of P-chiral analogues of oligonucleotides. Bioorg. Chem. 21: 127-155.
53. Levi, M., Biemond, B. J., van Zonneveld, A. J., ten Cate, J. W. and Pannekoek, H. (1992) Inhibition of plasminogen activator inhibitor-1 activity results in promotion of endogenous thrombolysis and inhibition of thrombus extension in models of experimental thrombosis. Circulation 85: 305-312.
54. Levin, E. G. (1986) Quantification and properties of the active and latent plasminogen activator inhibitors in cultures of human endothelial cells. Blood 67: 1309-1313.
55. MacKeller, C, Graham, D., Will, D. W., Burgess, S. and Brown, T. (1992) Synthesis and physical properties of anti-HIV antisense oligonucleotides bearing terminal lipophilic groups. Nucl. Acids Res. 20: 3411-3417.
56. Maeda, S., Abe, A., Seishima, M., Makino, K., Noma, A. and Kawade, M. (1989) Transient changes of serum lipoprotein(a) as an acute phase protein. Artherosclerosis 78: 145-150.
57. Marder, V. J. (1992) Inhibiting the inhibitor. Circulation 85: 386-387.
58. Mimuro, J. and Loskutoft, D. J. (1989) Purification of a protein from bovine plasma that binds to type 1 plasminogen activator inhibitor and prevents its interaction with extracellular matrix: evidence that the protein is vitronectin. J. Biol. Chem. 264: 936-919.
59. Nachman, R. L., Hajjar, K. A., Silverstein, R. L. and Dinarello, C. A. (1986) Interieukin 1 induces endothelial cell synthesis of plasminogen activator inhibitor. J. Exp. Med. 163: 1595-1600.
60. 35S]methionine into proteins secreted by African green monkey (BSC-1) cells. Proc. Natl. Acad. Sci. USA 80: 5636-5640.
61. Ny, T., Bjersing, L., Hsueh, A. J. and Loskutoff, D. J. (1985) Cultured granulosa cells produce two plasminogen activators and an antiactivator, each regulated differently by gonadotropins. Endocrinology 116: 1666-1668.
62. Ortigao, J. F., Ruck, A., Gupta, K. C., Rosch, R., Steiner, R. and Seliger, H. (1993) Solid-phase introduction and intracellular photoinduced reaction of water-soluble meso-tetracarhoxyporphine conjugated to an antisense oligodeoxyrihonucleotide. Biochimie 75: 29-34.
63. Pawłowska, Z., Pluskota, E., Chabielska, E., Buczko, W., Okruszek, A., Stec, W. J. and Cierniewski, C. S. (1997) Oligodeoxynucleotides antisense to PAI-1 mRNA increase fibrinolysis and modify experimental thrombosis in rats. Thromb. Haemost., in press.
64. Pralong, G., Calandra, T., Glauser, M. P., Schellekens, J. Verhoef, J., Bachmann, F. and Kruithoff, E. K. (1989) Plasminogen activator inhibitor 1: a new prognostic marker in septic shock. Thromb. Haemost. 61: 459-462.
65. Ramirez, F., Mandal, S. B. and Marecek, J. F. (1982) Nuleotidophosphoplipids: oligonucleotide derivatives with membrane-recognition groups. J. Am. Chem. Soc. 104: 5483-5486.
66. Reyers, I., Mussoni, L., Donati, M. B. and de Gaetano, G. (1980) Failure of aspirin at different doses to modify experimental thrombosis in rats. Thromb. Res. 18: 669-674.
67. Sanghvi, Y. S. and Dan Cook, P. (eds.) (1994) Carbohydrate Modifications in Antisense Research. ACS Symposium Series 580, Washington, DC.
68. Sawa, H., Sobel, B. E. and Fuji, S. (1994) Inhibition of type-1 plasminogen activator inhibitor production by antisense oligonucleotides in human vascular endothelial and smooth muscle cells. J. Biol. Chem. 269: 14149-14152.
69. Schneiderman, J., Sawdey, M. S., Keeton, M. R., Bordin, G. M., Bernstein, E. F., Dilley, R. B. and Loskutoff, D. J. (1992) Increased type 1 plasminogen activator inhibitor gene expression in atherosclerotic human arteries. Proc. Natl. Acad. Sci. USA 89: 6998-7002.
70. Stec, W. J. (1993) Stereoeontrolled synthesis of P-chiral analogues of oligonucleotides. In: Antisense Research and Applications pp. 251-273, Crooke, S. T. and Lebleu, B. (eds.) CRC Press. Boca Raton.
71. Stec, W. J., Cierniewski, Cz. S., Okruszek, A., Kobylański, A., Pawałoska, Z., Koziołkiewicz, M., Pluskota, E., Maciaszek, A., Rȩbowska, B. and Stasiak, M. (1997) Stereodependent inhibition of plasminogen activator inhibitor type 1 by phosphorothioate oligonucleotides: proof of sequence specificity in cell culture and in vivo rats experiments. Antisense Nucl. Acid Drug Dev., in press.
72. Stec, W. J. and Leśnikowski, Z. J. (1993) Stereospecific synthesis of P-chiral analogs of oligonucleotides. In: Protocols for Oligonucleotides and Analogs, pp. 285-313, Agrawal, S. (ed.) Humana Press, Totowa.
73. Stec, W. J. and Wilk, A. (1994) Stereocontrolled synthesis of oligo(nucleoside phosphorothioate)s. Angew. Chem. Int. Ed. Engl. 33: 709-722.
74. Stec, W. J., Grajkowski, A., Karwowski, B., Kobylańska, A., Koziołkiewicz, M., Misiura, K., Okruszek, A., Wilk, A., Guga, P. and Boczkowska, M. (1995) Diastereomers of nucleoside 3′-O-[2-thio-1.3.2-oxathia(selena)phospholanes]: building blocks for stereocontrolled synthesis of oligo(nucleoside phosphorothioate)s. J. Am. Chem. Soc. 117: 12019-12029.
75. Stec, W. J., Grajkowski, A., Koziołkiewicz, M. and Uznański, B. (1991) Novel route to oligo(deoxyribonucleotide phosphorothioates): stereocontrolled synthesis of P-chiral oligo(deoxyribonucleotide phosphorothioates). Nucl. Acids Res. 19: 5883-5888.
76. Stec, W. J., Zon, G., Egan, W. and Stec, B. (1984) Automated solid-phase synthesis, separation, and stereochemistry of phosphorothioate analogues of oligodeoxyribonucleotides. J. Am. Chem. Soc. 106: 6077-6079.
77. Stec, W. J., Zon, G. and Iznański, B. (1985) Reversed-phase high-performance liquid chromantographic separation of diastereomeric phosphorothioate analogues of oligodeoxyribonucleotides and other back-bone-modified congeners of DNA. J. Chromatogr. 326: 263-280.
78. Stein, C. A. (1995) Does antisense exist? Nat. Med 1: 1119-1121.
79. Stein, C. A. and Cheng, Y.-C. (1993) Antisense oligonucleotides as therapeutic agents: is the bullet really magical? Science 261: 1004-1012.
80. Tamura, N., Iwatani, W., Shoji, Y., Shimada, J. and Mizushima, Y. (1995) Aptameric inhibition of in vitro DNA polymerization by phosphorothioate oligonucleotides. Nucl. Acids Res. Symp. Ser. 34: 93-94.
81. Tang, J., Roskey, A., Li, Y. and Agrawal, S. (1995) Enzymatic synthesis of stereoregular (All-Rp) oligonucleotide phosphorothioate and its properties. Nucleosides Nucleotides 14: 985-990.
82. Thalacker, F. W. and Nilsen-Hamilton, M. (1987) Specific induction of secreted proteins by transforming growth factor-beta and 12-O-terradecanoylphorbol-13-acetate: relationship with an inhibitor of plasminogen activator. J. Biol. Chem. 262: 2283-2290.
83. Vague, P., Juhan-Vague, I., Aillaud, M. F., Badier, C., Viard, R., Alessi, M. C. and Collen, D. (1986) Correlation between blood fibrinolytic activity, plasminogen activator inhibitor level, plasma insulin level, and relative body weight in normal and obese subjects. Metabolism 35: 250-253.
84. van Hinsbergh, V. W., Bertina, R. M., van Wijngaarden, A., van Tilburg, N. H., Emeis, J. J. and Haverkate, F. (1985) Activated protein G decreases plasminogen activator-inhibitor activity in endothelial cell-conditioned medium. Blood 65: 444-451.
85. van Mourik, J. A., Lawrence, D. A. and Loskutoff, D. J. (1984) Purification of an inhibitor of plasminogen activator (antiactivator) synthesized by endothelial cells. J. Biol. Chem. 259: 14914-14921.
86. Vassalli, J. D., Sappino, A. P. and Belin, D. (1991) The plasminogen activator/plasmin system. J. Clin. Invest. 88: 1067-1072.
87. Wagner, R. W. (1995) The state of the art in antisense research. Nat. Med. 1: 1116-1118.
88. Wilk, A. and Stec, W. J. (1995) Analysis of oligo(deoxynucleotide phosphorothioate)s and their diastereomeric composition. Nucl. Acids Res. 23: 530-534
89. Wiman, B. and Hamsten, A. (1990) The fibrinolytic enzyme system and its role in the etiology of thromboembolic disease. Semin. Thromb. Haemost. 26: 207-216.
90. Zamecnik, P. C. and Stephenson, M. L. (1978) Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligonucleotide. Proc. Natl. Acad. Sci. USA 75: 280-284.
91. Zeheb, R. and Gelehrter, T. D. (1988) Cloning and sequencing of cDNA for the rat plasminogen activator inhibitor-1. Gene 73: 459-468.
92. Zon, G. and Stec, W. J. (1991) Phosphorothioate oligonucleotides. In: Oligonucleotides and Analogues, pp. 87-108, Eckstein, F. (ed.) IRL Press, Oxford.